Literature DB >> 19828881

Antagonism of aryl hydrocarbon receptor signaling by 6,2',4'-trimethoxyflavone.

Iain A Murray1, Colin A Flaveny, Brett C DiNatale, Chris R Chairo, Jennifer C Schroeder, Ann Kusnadi, Gary H Perdew.   

Abstract

The aryl hydrocarbon receptor (AHR) is regarded as an important homeostatic transcriptional regulator within physiological and pathophysiological processes, including xenobiotic metabolism, endocrine function, immunity, and cancer. Agonist activation of the AHR is considered deleterious based on toxicological evidence obtained with environmental pollutants, which mediate toxic effects through AHR. However, a multitude of plant-derived constituents, e.g., polyphenols that exhibit beneficial properties, have also been described as ligands for the AHR. It is conceivable that some of the positive aspects of such compounds can be attributed to suppression of AHR activity through antagonism. Therefore, we conducted a dioxin response element reporter-based screen to assess the AHR activity associated with a range of flavonoid compounds. Our screen identified two flavonoids (5-methoxyflavone and 7,4'-dimethoxyisoflavone) with previously unidentified AHR agonist potential. In addition, we have identified and characterized 6,2',4'-trimethoxyflavone (TMF) as an AHR ligand that possesses the characteristics of an antagonist having the capacity to compete with agonists, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin and benzo[a]pyrene, thus effectively inhibiting AHR-mediated transactivation of a heterologous reporter and endogenous targets, e.g., CYP1A1, independent of cell lineage or species. Furthermore, TMF displays superior action by virtue of having no partial agonist activity, in contrast to other documented antagonists, e.g., alpha-napthoflavone, which are partial weak agonists. TMF also exhibits no species or promoter dependence with regard to AHR antagonism. TMF therefore represents an improved tool allowing for more precise dissection of AHR function in the absence of any conflicting agonist activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828881      PMCID: PMC2802483          DOI: 10.1124/jpet.109.158261

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  beta-naphthoflavone, an inducer of xenobiotic metabolizing enzymes, inhibits firefly luciferase activity.

Authors:  Thomas T Y Wang
Journal:  Anal Biochem       Date:  2002-05-01       Impact factor: 3.365

2.  Modulation of Th17 development and function by activation of the aryl hydrocarbon receptor--the role of endogenous ligands.

Authors:  Brigitta Stockinger; Marc Veldhoen; Keiji Hirota
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

3.  Transient expression of CYP1A1 in rat epithelial cells cultured in suspension.

Authors:  S A Monk; M S Denison; R H Rice
Journal:  Arch Biochem Biophys       Date:  2001-09-01       Impact factor: 4.013

4.  2,3,7,8-tetrachlorodibenzo-p-dioxin-induced degradation of aryl hydrocarbon receptor (AhR) by the ubiquitin-proteasome pathway. Role of the transcription activaton and DNA binding of AhR.

Authors:  Q Ma; K T Baldwin
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

5.  Ligand-dependent and independent modulation of aryl hydrocarbon receptor localization, degradation, and gene regulation.

Authors:  Zhijuan Song; Richard S Pollenz
Journal:  Mol Pharmacol       Date:  2002-10       Impact factor: 4.436

6.  Species-specific transcriptional activity of synthetic flavonoids in guinea pig and mouse cells as a result of differential activation of the aryl hydrocarbon receptor to interact with dioxin-responsive elements.

Authors:  Jun-Guo Zhou; Ellen C Henry; Christine M Palermo; Stephen D Dertinger; Thomas A Gasiewicz
Journal:  Mol Pharmacol       Date:  2003-04       Impact factor: 4.436

7.  Ligand selectivity and gene regulation by the human aryl hydrocarbon receptor in transgenic mice.

Authors:  Colin A Flaveny; Iain A Murray; Chris R Chiaro; Gary H Perdew
Journal:  Mol Pharmacol       Date:  2009-03-19       Impact factor: 4.436

8.  3'-methoxy-4'-nitroflavone, a reported aryl hydrocarbon receptor antagonist, enhances Cyp1a1 transcription by a dioxin responsive element-dependent mechanism.

Authors:  Junguo Zhou; Thomas A Gasiewicz
Journal:  Arch Biochem Biophys       Date:  2003-08-01       Impact factor: 4.013

9.  Aryl hydrocarbon receptor polymorphism modulates DMBA-induced inflammation and carcinogenesis in phenotypically selected mice.

Authors:  Vinicius R C De Souza; Wafa K Cabrera; Antonella Galvan; Orlando G Ribeiro; Marcelo De Franco; Francisca Vorraro; Nancy Starobinas; Solange Massa; Tommaso A Dragani; Olga M Ibañez
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

10.  Ah receptor represses acute-phase response gene expression without binding to its cognate response element.

Authors:  Rushang D Patel; Iain A Murray; Colin A Flaveny; Ann Kusnadi; Gary H Perdew
Journal:  Lab Invest       Date:  2009-03-30       Impact factor: 5.662

View more
  25 in total

1.  Transcriptional and posttranslational inhibition of dioxin-mediated induction of CYP1A1 by harmine and harmol.

Authors:  Mohamed A M El Gendy; Anatoly A Soshilov; Michael S Denison; Ayman O S El-Kadi
Journal:  Toxicol Lett       Date:  2011-10-06       Impact factor: 4.372

2.  In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo.

Authors:  Ashley J Parks; Michael P Pollastri; Mark E Hahn; Elizabeth A Stanford; Olga Novikov; Diana G Franks; Sarah E Haigh; Supraja Narasimhan; Trent D Ashton; Timothy G Hopper; Dmytro Kozakov; Dimitri Beglov; Sandor Vajda; Jennifer J Schlezinger; David H Sherr
Journal:  Mol Pharmacol       Date:  2014-08-26       Impact factor: 4.436

3.  Ligand-independent activation of aryl hydrocarbon receptor signaling in PCB3-quinone treated HaCaT human keratinocytes.

Authors:  Wusheng Xiao; Jyungmean Son; Sabine U Vorrink; Frederick E Domann; Prabhat C Goswami
Journal:  Toxicol Lett       Date:  2015-02-07       Impact factor: 4.372

4.  Identification of a high-affinity ligand that exhibits complete aryl hydrocarbon receptor antagonism.

Authors:  Kayla J Smith; Iain A Murray; Rachel Tanos; John Tellew; Anthony E Boitano; William H Bisson; Siva K Kolluri; Michael P Cooke; Gary H Perdew
Journal:  J Pharmacol Exp Ther       Date:  2011-04-14       Impact factor: 4.030

5.  Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor.

Authors:  Benjamin J Moyer; Itzel Y Rojas; Iain A Murray; Seokwon Lee; Haley F Hazlett; Gary H Perdew; Craig R Tomlinson
Journal:  Toxicol Appl Pharmacol       Date:  2017-03-20       Impact factor: 4.219

Review 6.  Aryl hydrocarbon receptor ligands in cancer: friend and foe.

Authors:  Iain A Murray; Andrew D Patterson; Gary H Perdew
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

7.  Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3',4'-dimethoxy-α-naphthoflavone.

Authors:  Iain A Murray; Colin A Flaveny; Christopher R Chiaro; Arun K Sharma; Rachel S Tanos; Jennifer C Schroeder; Shantu G Amin; William H Bisson; Siva K Kolluri; Gary H Perdew
Journal:  Mol Pharmacol       Date:  2010-12-02       Impact factor: 4.436

8.  Microbiota Metabolism Promotes Synthesis of the Human Ah Receptor Agonist 2,8-Dihydroxyquinoline.

Authors:  Troy D Hubbard; Qing Liu; Iain A Murray; Fangcong Dong; Charles Miller; Philip B Smith; Krishne Gowda; Jyh Ming Lin; Shantu Amin; Andrew D Patterson; Gary H Perdew
Journal:  J Proteome Res       Date:  2019-03-04       Impact factor: 4.466

9.  Development of novel CH223191-based antagonists of the aryl hydrocarbon receptor.

Authors:  Eun-Young Choi; Hyosung Lee; R W Cameron Dingle; Kyung Bo Kim; Hollie I Swanson
Journal:  Mol Pharmacol       Date:  2011-10-03       Impact factor: 4.436

Review 10.  Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders.

Authors:  Philip B Busbee; Michael Rouse; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Nutr Rev       Date:  2013-04-01       Impact factor: 7.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.